This filing does not create new dilution — the 551,724 shares were already issued/pre-funded on May 4, 2026. The only new information is that Ascendant can now resale into the market once lock-up expires (50% at ~Oct 27, 2026). Monitor for actual selling patterns rather than filing impact.
Price Chart
Executive Summary
Cue Biopharma filed an S-3 registration statement to register 551,724 shares of common stock for resale by Ascendant Health Sciences, a strategic licensee. These shares are issuable upon exercise of pre-funded warrants granted as partial consideration for a license to CUE-221, an anti-IgE antibody in Phase 2 development. The filing is a routine contractual obligation — no new primary offering, no new dilution beyond the already-issued warrants, and the company receives no proceeds except nominal cash exercise amounts.
Key Facts
- Shelf registration for resale of 551,724 shares by Ascendant Health Sciences (selling stockholder) following their May 4, 2026 private placement.
- Warrants acquired via April 30, 2026 securities purchase agreement — part of consideration for CUE-221 license deal with $15M upfront and up to $676.5M in milestones.
- Company receives no proceeds from resale; only nominal $0.001/share exercise price if warrants exercised for cash.
- Ascendant is locked up: 50% released at 180 days, additional 25% at 270 days, remaining 25% at 360 days from license date (April 30, 2026).
- CUE closed at $26.73 on June 17, 2026, and the company had 4,200,343 shares outstanding as of June 1, 2026 (post-closing).
- The 10-Q filed May 14, 2026 disclosed recurring operating losses and substantial doubt about going concern.
Financial Impact
Maximum theoretical market value of registered shares based on June 17 price: 551,724 × $26.73 ≈ $14.7M. No cash impact to company.
Risk Factors
- Potential overhang from Ascendant's eventual 551,724-share resale after lock-up expiration (starting ~October 27, 2026).
- Company remains a clinical-stage biotech with no approved products and going concern uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-275808 |
| Document: d44856dexfilingfees.htm | 0001193125-26-275808 |
| Document: d44856dex51.htm | 0001193125-26-275808 |
| Document: d44856dex231.htm | 0001193125-26-275808 |
| Document: 0001193125-26-275808-index-headers.html | 0001193125-26-275808 |
| Document: 0001193125-26-275808-index.html | 0001193125-26-275808 |
| Document: 0001193125-26-275808.txt | 0001193125-26-275808 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.45 (+1.18%) |
Oct 13, 2026 13d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.45 (−0.81%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.45 (−17.38%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.45 (+23.06%) |
Aug 17, 2026 10w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.45 (+28.21%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.45 (−33.25%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.45 (−46.05%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.45 (−49.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers